The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Hosted virtual Analyst Day showcasing lead program KRRO-121’s potential to be a first-in-class transformational treatment for hyperammonemia in ...
- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a ...
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Wednesday, May 21, 2025, at 2:35 p.m. ET. Dr. Aiyar and Dr. Olugemo ...
Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting ...
Korro Bio's lead asset is expected to enter a Phase 1/2 trial in adult A1ATD patients in the second half of 2024. Analyst writes Korro's preclinical data package, particularly in the NSG PiZ mouse ...
Korro Bio, Inc. ( (KRRO)) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors. Korro Bio, Inc. is a biopharmaceutical company specializing ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines, today announced the completion of a $116M Series ...
CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
KRRO-121 for hyperammonemia in patients with urea cycle disorders Korro’s GalNAc-conjugated oligonucleotide intended for patients with alpha-1 antitrypsin deficiency Company expects proceeds to extend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results